Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Express Scripts
Medtronic
Colorcon

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Papaverine

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Papaverine?

Papaverine is an investigational drug.

There have been 16 clinical trials for Papaverine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Erectile Dysfunction, Enuresis, and Cognition Disorders. The leading clinical trial sponsors are Cairo University, National Cancer Institute (NCI), and Ohio State University Comprehensive Cancer Center.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for Papaverine
TitleSponsorPhase
Effect of Papaverine on Renal Artery Blood Flow VolumeAsan Medical CenterPhase 4
Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric PatientsThe University of Texas Health Science Center, HoustonPhase 4
Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With EDBenha UniversityPhase 2/Phase 3

See all Papaverine clinical trials

Clinical Trial Summary for Papaverine

Top disease conditions for Papaverine
Top clinical trial sponsors for Papaverine

See all Papaverine clinical trials

US Patents for Papaverine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Papaverine   Start Trial Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)   Start Trial
Papaverine   Start Trial Implantable human liver tissue constructs and uses thereof Massachusetts Institute of Technology (Cambridge, MA)   Start Trial
Papaverine   Start Trial Cytochrome P450 fusion protein The University of York (York, GB) Sun Pharmaceutical Industries (Australia) Pty Ltd (Notting Hill, Victoria, AU)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Papaverine

Drugname Country Document Number Estimated Expiration Related US Patent
Papaverine World Intellectual Property Organization (WIPO) 2014052836 2032-09-27   Start Trial
Papaverine World Intellectual Property Organization (WIPO) 2012048170 2030-10-06   Start Trial
Papaverine Australia 2015261278 2034-05-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Merck
Baxter
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.